Frequency Therapeutics is pioneering a new category in regenerative medicine. Frequency’s progenitor cell activation platform aims to restore human function by developing therapeutics that activate a person’s innate regenerative potential within the body. The Company’s lead preclinical program is designed to activate oligodendrocyte precursor cells with the goal of driving remyelination and potential functional recovery for individuals living with multiple sclerosis. Frequency Therapeutics (Frequency; Nasdaq: FREQ) announced a business combination with Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA. The combined company will operate under the name Korro Bio, Inc., and its shares are expected to begin trading on the Nasdaq Capital Market under the ticker symbol “KRRO” on November 6, 2023.